Cue Biopharma announced the appointment of Pamela Garzone, Ph.D., to its board of directors. She is currently the chief development officer of Anixa Biosciences, where she oversees a portfolio in oncology.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CUE:
- Cue Biopharma appoints Verheyen to board of directors
- Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
- 2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
- Cue Biopharma price target lowered to $8 from $9 at Stifel
- Cue Biopharma reports Q4 EPS (37c) vs (26c) last year
Questions or Comments about the article? Write to editor@tipranks.com